Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance

被引：33
作者：
Hogan, Jonathan J. [1 ]
Weiss, Brendan M. [2 ]
机构：
[1] Univ Penn, Div Nephrol, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2016年 / 11卷 / 09期
关键词：
MULTIPLE-MYELOMA PATIENTS; CHRONIC LYMPHOCYTIC-LEUKEMIA; LENALIDOMIDE PLUS DEXAMETHASONE; MINIMAL RESIDUAL DISEASE; CHAIN DEPOSITION DISEASE; SINGLE-AGENT CARFILZOMIB; MANTLE-CELL LYMPHOMA; TERM-FOLLOW-UP; OPEN-LABEL; FLOW-CYTOMETRY;
D O I：
10.2215/CJN.03160316
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The monoclonal gammopathies of renal significance (MGRS) are a group of disorders characterized by monoclonal Ig deposition in the kidney, but are not associated with systemic lymphoma or overt multiple myeloma. The prevailing hypothesis is that the pathogenic paraproteins in MGRS are produced by underlying B cell or plasma cell clones. However, in the MGRS literature, the yield of detecting a clone has been variable, and progression to ESRD is common. Here, we present an "onco-nephrologic" approach to the MGRS disorders by highlighting recent advances in lymphoma and multiple myeloma that can be used in the evaluation and management of these patients.
引用
收藏
页码：1681 / 1691
页数：11
相关论文
共 65 条
  • [21] A case of recurrent light chain deposition disease after living-related renal transplantation - detailed process of the recurrence
    Horike, Keiji
    Takeda, Asami
    Otsuka, Yasuhiro
    Inaguma, Daijyo
    Goto, Norihiko
    Watarai, Yoshihiko
    Uchida, Kazuharu
    Morozumi, Kunio
    [J]. CLINICAL TRANSPLANTATION, 2012, 26 : 64 - 69
  • [22] Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays
    Katzmann, Jerry A.
    Dispenzieri, Angela
    Kyle, Robert A.
    Snyder, Melissa R.
    Plevak, Matthew F.
    Larson, Dirk R.
    Abraham, Roshini S.
    Lust, John A.
    Melton, L. Joseph, III
    Rajkumar, S. Vincent
    [J]. MAYO CLINIC PROCEEDINGS, 2006, 81 (12) : 1575 - 1578
  • [23] Pentostatin and Rituximab Therapy for Previously Untreated Patients With B-Cell Chronic Lymphocytic Leukemia
    Kay, Neil E.
    Wu, Wenting
    Kabat, Brian
    LaPlant, Betsy
    Lin, Thomas S.
    Byrd, John C.
    Jelinek, Diane F.
    Greyer, Michael R.
    Zent, Clive S.
    Call, Timothy G.
    Shanafelt, Tait D.
    [J]. CANCER, 2010, 116 (09) : 2180 - 2187
  • [24] Knop S, 2005, HAEMATOLOGICA, V90, P1287
  • [25] A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Offord, JR
    Larson, DR
    Plevak, MF
    Melton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) : 564 - 569
  • [26] Prevalence of monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Larson, DR
    Plevak, MF
    Offord, JR
    Dispenzieri, A
    Katzmann, JA
    Melton, LJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13) : 1362 - 1369
  • [27] Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
    Landgren, Ola
    Gormley, Nicole
    Turley, Danielle
    Owen, Roger G.
    Rawstron, Andy
    Paiva, Bruno
    Barnett, David
    Arroz, Maria
    Wallace, Paul
    Durie, Brian
    Yuan, Constance
    Dogan, Ahmet
    Stetler-Stevenson, Maryalice
    Marti, Gerald E.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (12) : 1159 - 1160
  • [28] Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
    Leung, Nelson
    Bridoux, Frank
    Hutchison, Colin A.
    Nasr, Samih H.
    Cockwell, Paul
    Fermand, Jean-Paul
    Dispenzieri, Angela
    Song, Kevin W.
    Kyle, Robert A.
    [J]. BLOOD, 2012, 120 (22) : 4292 - 4295
  • [29] Association of response endpoints with survival outcomes in multiple myeloma
    Lonial, S.
    Anderson, K. C.
    [J]. LEUKEMIA, 2014, 28 (02) : 258 - 268
  • [30] Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
    Lonial, Sagar
    Weiss, Brendan M.
    Usmani, Saad Z.
    Singhal, Seema
    Chari, Ajai
    Bahlis, Nizar J.
    Belch, Andrew
    Krishnan, Amrita
    Vescio, Robert A.
    Victoria Mateos, Maria
    Mazumder, Amitabha
    Orlowski, Robert Z.
    Sutherland, Heather J.
    Blade, Joan
    Scott, Emma C.
    Oriol, Albert
    Berdeja, Jesus
    Gharibo, Mecide
    Stevens, Don A.
    LeBlanc, Richard
    Sebag, Michael
    Callander, Natalie
    Jakubowiak, Andrzej
    White, Darrell
    de la Rubia, Javier
    Richardson, Paul G.
    Lisby, Steen
    Feng, Huaibao
    Uhlar, Clarissa M.
    Khan, Imran
    Ahmadi, Tahamtan
    Voorhees, Peter M.
    [J]. LANCET, 2016, 387 (10027) : 1551 - 1560
1234567